- Home
- NVX vs ATYR Comparison
NVX vs ATYR Comparison
Compare NVX & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVX
- ATYR
- Stock Information
- Founded
- NVX 2012
- ATYR 2005
- Country
- NVX Australia
- ATYR United States
- Employees
- NVX N/A
- ATYR N/A
- Industry
- NVX Industrial Machinery/Components
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVX Miscellaneous
- ATYR Health Care
- Exchange
- NVX Nasdaq
- ATYR Nasdaq
- Market Cap
- NVX 254.2M
- ATYR 228.1M
- IPO Year
- NVX N/A
- ATYR 2015
- Fundamental
- Price
- NVX $1.66
- ATYR $3.30
- Analyst Decision
- NVX Strong Buy
- ATYR Strong Buy
- Analyst Count
- NVX 1
- ATYR 4
- Target Price
- NVX $4.00
- ATYR $19.25
- AVG Volume (30 Days)
- NVX 314.2K
- ATYR 832.1K
- Earning Date
- NVX 01-01-0001
- ATYR 11-07-2024
- Dividend Yield
- NVX N/A
- ATYR N/A
- EPS Growth
- NVX N/A
- ATYR N/A
- EPS
- NVX N/A
- ATYR N/A
- Revenue
- NVX $6,875,112.00
- ATYR $235,000.00
- Revenue This Year
- NVX $89.31
- ATYR N/A
- Revenue Next Year
- NVX $410.89
- ATYR $1,200.54
- P/E Ratio
- NVX N/A
- ATYR N/A
- Revenue Growth
- NVX 19.05
- ATYR N/A
- 52 Week Low
- NVX $1.40
- ATYR $1.34
- 52 Week High
- NVX $3.10
- ATYR $3.80
- Technical
- Relative Strength Index (RSI)
- NVX 40.10
- ATYR 52.43
- Support Level
- NVX $1.50
- ATYR $3.05
- Resistance Level
- NVX $1.88
- ATYR $3.26
- Average True Range (ATR)
- NVX 0.11
- ATYR 0.22
- MACD
- NVX -0.02
- ATYR -0.03
- Stochastic Oscillator
- NVX 21.28
- ATYR 30.00
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration and Mining, Battery Technology, and NOVONIX Anode Materials. Graphite Exploration and Mining segment is engaged in the exploration and development of high-grade flake graphite deposits. The NOVONIX Anode Materials segment develops and manufactures battery anode materials. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Technology segment generates maximum revenue for the company.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.